The National Organization for Rare Disorders (NORD)’s RareLaunch training program will host two days of…
Articles by Marisa Wexler, MS
A majority of rare disease patients using telehealth during the COVID-19 pandemic thought the experience positive, and many would like…
Newly raised equity financing will advance Galecto‘s clinical pipeline, which includes GB0139, a potential inhalation treatment for idiopathic…
In recognition of September being Pulmonary Fibrosis Awareness Month, the Pulmonary Fibrosis Foundation (PFF) is working to raise awareness…
In the U.S., idiopathic pulmonary fibrosis (IPF) mortality rates decreased from 2004 to 2017, a new study shows. The…
AbbVie will assume development of Morphic Therapeutic‘s alpha v beta 6 (αvβ6) integrin inhibitors as potential treatments for…
People with idiopathic pulmonary fibrosis (IPF) who are treated with either Ofev (nintedanib) or Esbriet (pirfenidone) report…
The first participant has been enrolled in a Phase 3 clinical trial evaluating Ofev (nintedanib) in children with…
People with idiopathic pulmonary fibrosis (IPF) are at increased risk of several cancers other than lung cancer, a new…
The European Commission has approved Boehringer Ingelheim‘s Ofev (nintedanib)Â for the treatment of progressive fibrosing interstitial…